MyChart®
Online Access to Your clonoSEQ Results
MyChart offers blood cancer patients online access to their clonoSEQ test results, allowing you to securely receive important information about you or your child’s health.
Download our clonoSEQ MyChart Resource
Adaptive Assist™
A patient support program designed to help you navigate insurance, financial assistance, and more.
This page is intended for a US-based audience.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.
MyChart is a trademark of Epic Systems Corporation.